Literature DB >> 27536596

Nonsurgical Treatment Strategies after Osteoporotic Hip Fractures.

Byung-Woo Min1, Kwang-Soon Song1, Ki-Cheor Bae1, Chul-Hyun Cho1, Eun-Suck Son1, Kyung-Jae Lee1.   

Abstract

Osteoporosis is a metabolic disease that is increasing in prevalence as people live longer. Because the orthopedic surgeon is frequently the first and often the only physician to manage patients with osteoporotic hip fractures, every effort should be made to prevent future fractures. A multidisciplinary approach is essential in treatment of osteoporotic fractures. Basic treatment includes calcium and vitamin D supplementation, fall prevention, hip protection, and balance and exercise programs. Currently available pharmacologic agents are divided into antiresorptive and anabolic groups. Antiresorptive agents such as bisphosphonates limit bone resorption through inhibition of osteoclastic activity. Anabolic agents such as parathyroid hormone promote bone formation.

Entities:  

Keywords:  Hip fractures; Medication; Osteoporosis

Year:  2015        PMID: 27536596      PMCID: PMC4972623          DOI: 10.5371/hp.2015.27.1.9

Source DB:  PubMed          Journal:  Hip Pelvis        ISSN: 2287-3260


  38 in total

Review 1.  Can bisphosphonates be given to patients with fractures?

Authors:  H Fleisch
Journal:  J Bone Miner Res       Date:  2001-03       Impact factor: 6.741

2.  2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary.

Authors:  Alexandra Papaioannou; Suzanne Morin; Angela M Cheung; Stephanie Atkinson; Jacques P Brown; Sidney Feldman; David A Hanley; Anthony Hodsman; Sophie A Jamal; Stephanie M Kaiser; Brent Kvern; Kerry Siminoski; William D Leslie
Journal:  CMAJ       Date:  2010-10-12       Impact factor: 8.262

3.  Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy?

Authors:  Yong-Chan Ha; Myung-Rae Cho; Ki Hong Park; Shin-Yoon Kim; Kyung-Hoi Koo
Journal:  Clin Orthop Relat Res       Date:  2010-09-24       Impact factor: 4.176

Review 4.  The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.

Authors:  Yoshiyuki Yasuda; Jadwiga Kaleta; Dieter Brömme
Journal:  Adv Drug Deliv Rev       Date:  2005-04-15       Impact factor: 15.470

5.  Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra.

Authors:  Satoshi Komatsubara; Satoshi Mori; Tasuku Mashiba; Masako Ito; Jiliang Li; Yoshio Kaji; Tomoyuki Akiyama; Kensaku Miyamoto; Yongping Cao; Jun Kawanishi; Hiromichi Norimatsu
Journal:  J Bone Miner Res       Date:  2003-03       Impact factor: 6.741

6.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

Review 7.  Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David W Dempster; Peter R Ebeling; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Tet Sen Howe; Marjolein C H van der Meulen; Robert S Weinstein; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2013-10-01       Impact factor: 6.741

8.  DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass.

Authors:  S L Bonnick; T J Beck; F Cosman; M C Hochberg; H Wang; A E de Papp
Journal:  Osteoporos Int       Date:  2008-10-02       Impact factor: 4.507

Review 9.  Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis.

Authors:  Mark J Bolland; Alison Avenell; John A Baron; Andrew Grey; Graeme S MacLennan; Greg D Gamble; Ian R Reid
Journal:  BMJ       Date:  2010-07-29

Review 10.  A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record.

Authors:  Mark J Bolland; Andrew Grey
Journal:  BMJ Open       Date:  2014-10-07       Impact factor: 2.692

View more
  2 in total

1.  Clinical Results of Complex Subtrochanteric Femoral Fractures with Long Cephalomedullary Hip Nail.

Authors:  Kwang-Kyoun Kim; Yougun Won; Danica H Smith; Gi-Soo Lee; Hee Young Lee
Journal:  Hip Pelvis       Date:  2017-06-02

Review 2.  Development and Clinical Application of Phosphorus-Containing Drugs.

Authors:  Hanxiao Yu; He Yang; Enxue Shi; Wenjun Tang
Journal:  Med Drug Discov       Date:  2020-08-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.